… extensive-stage small cell lung cancer, according to study results … ‘Devastating diagnosis’ Small cell lung cancer — the most aggressive subtype … of lung cancer cases. About 70% of small cell lung cancers are … ), a novel DNA-damaging agent, is active in the …

Small cell lung cancer (SCLC), a highly aggressive and … . Recent advances in immunotherapy, targeted agents, and novel drug combinations have … landscape remains fragmented, with few agents advancing beyond early phases. This …

… Additionally, in mice with lung cancer and pulmonary metastases, slowing … 106 cells to A549 lung cancer cells.35 The obtained … as a potential delivery agent for neutron capture therapy. … Capture Therapy in the lung cancer treatment. Nanomedicine. 2015; …

… therapy lines in small cell lung cancer, with best responses seen in … at ASCO 2025, small cell lung cancer (SCLC) remains a particularly difficult … male (55%), with a median age of 65. Lurbinectedin was primarily …

… ’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has … -line extensive-stage small cell lung cancer (ES-SCLC) significantly reduced patients … a safer one. More novel agents are emerging. The DLL3 drug …

… officially entered the Japanese lung cancer market with their chemo- … or recurrent non-small cell lung cancer (NSCLC) with EGFR … s Pharmaceuticals and Medical Devices Agency (PMDA) granted approval  … trial. Japan’s reimbursement agency has priced the tablets …

… low-dose CT (LDCT) lung cancer screening exam.  New research … Lung Cancer Screening Trial (NLST). Experts believe Sybil could improve lung cancer … ,000 scans of patients ages 50 to 80 who … predicting who would develop lung cancer in the future based …

… Task Force guidelines for lung cancer screening (LCS) called … . Adjustments were made for age, race, smoking history, mental … women than men. In lung cancer in general, a shift … Association Between Sex and Lung Cancer Screening Adherence to Follow- …

… of resectable non-small cell lung cancer (NSCLC) at high risk of … . In addition to approvals in lung cancer, Opdivo-based options are also … -doublet chemotherapy, followed by single-agent Opdivo as adjuvant treatment after …

… extensive-stage small cell lung cancer (ES-SCLC). This ADC … million patients diagnosed with lung cancer globally each year. Notably … study in small cell lung cancer later this year, … frequent communication with the agency regarding the clinical development …